文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

玛伐凯泰在女性与男性梗阻性肥厚型心肌病患者中的疗效比较:EXPLORER-HCM研究分析

Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
PubMed 文献 · Circulation · 2023-11-14

EXPLORER-HCM试验的事后分析比较了玛伐凯泰在女性和男性梗阻性肥厚型心肌病患者中的疗效。基线时女性年龄更大、心功能更差,但治疗30周后,主要复合终点和多数次要终点的改善在两组相似,女性在健康状况和NT-proBNP水平上改善更显著。

要点

  • 女性梗阻性HCM患者基线年龄更大、心功能更差。
  • 玛伐凯泰治疗30周后主要终点改善无性别差异。
  • 女性在健康状况和NT-proBNP改善上优于男性。

核心结论

  • 尽管女性基线状况更差,玛伐凯泰在主要和多数次要终点上的改善与男性相似,且在健康状况和NT-proBNP上改善更显著。

研究设计与样本

  • EXPLORER-HCM研究的事后预设性别分析,盲法随机对照试验,纳入症状性梗阻性肥厚型心肌病患者,女性102例,男性149例。

主要发现

  • 基线时女性年龄62岁 vs 男性56岁(P<0.0001),峰值耗氧量16.7 vs 21.3 mL·kg-1·min-1(P<0.0001),NYHA III级比例42% vs 17%(P<0.0001),KCCQ-CSS 64 vs 75(P<0.0001),NT-proBNP 1704 vs 990 ng/L(P=0.004)。
  • 治疗30周后,主要复合终点玛伐凯泰 vs 安慰剂的百分比差异在女性为22%,男性为19%(P=0.759)。
  • 次要终点:运动后左室流出道压差变化女性-42.4 mmHg vs 男性-33.6 mmHg(P=0.348);峰值耗氧量变化1.2 vs 1.6 mL·kg-1·min-1(P=0.633);NYHA改善≥1级比例41% vs 28%(P=0.254)。
  • 女性在KCCQ-CSS改善(14.8 vs 6.1,P=0.026)和NT-proBNP水平下降(-1322 vs -649 ng/L,P=0.0008)上更显著。

临床怎么用

  • 玛伐凯泰治疗梗阻性HCM的疗效无显著性别差异,女性患者同样获益。
  • 女性患者基线心功能更差,应关注其健康状况改善和NT-proBNP下降。

局限性

  • 为事后分析,样本量有限,可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men in the EXPLORER-HCM study (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy). METHODS: A prespecified post hoc analysis of sex from the blinded, randomized EXPLORER-HCM trial of mavacamten versus placebo in symptomatic patients with obstructive HCM was performed. Baseline characteristics were compared with t tests for continuous variables (expressed as mean values) and χ2 tests for categorical variables. Prespecified primary, secondary, and exploratory end points and echocardiographic measurements from baseline to end of treatment (week 30) were analyzed with ANCOVA for continuous end points and a generalized linear model with binomial distribution for binary end points, with adjustment for each outcome's baseline value, New York Heart Association class, β-blocker use, and ergometer type. RESULTS: At baseline, women (n=102) were older (62 years versus 56 years; P<0.0001), had lower peak oxygen consumption (16.7 mL·kg-1·min-1 versus 21.3 mL·kg-1·min-1; P<0.0001), were more likely to be assigned New York Heart Association class III (42% versus 17%; P<0.0001), had worse health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 64 versus 75; P<0.0001), and had higher baseline plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (1704 ng/L versus 990 ng/L; P=0.004) than men (n=149). After 30 weeks of mavacamten treatment, similar improvements were observed in women and men in the primary composite end point (percentage difference on mavacamten versus placebo, 22% versus 19%, respectively; P=0.759) and in the secondary end points of change in postexercise left ventricular outflow tract gradient (-42.4 mm Hg versus -33.6 mm Hg; P=0.348), change in peak oxygen consumption (1.2 mL·kg-1·min-1 versus 1.6 mL·kg-1·min-1; P=0.633), and percentage achieving ≥1 New York Heart Association class improvement (41% versus 28%; P=0.254). However, women had greater improvement in health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 14.8 versus 6.1; P=0.026) and in the exploratory end point of NT-proBNP levels (-1322 ng/L versus -649 ng/L; P=0.0008). CONCLUSIONS: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03470545.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Cresci S, Bach RG, Saberi S, et al. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. 2023. PMID: 37961906. doi:10.1161/CIRCULATIONAHA.123.065600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。